LUCIUS 卢修斯 吡托布鲁替尼 Pirtobrutinib细胞淋巴瘤

吡托布鲁替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Pirtobrutinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:

细胞淋巴瘤

Each film-coated tablet contains

LUCIUS

Dirtobrutinib .........

PHARMACEUTICALS

Indication:

LuciPirto is a kinase inhibitor indicated for
the treatment of adult patients with relapsed
or refractory mantle cell lymphoma (MCL)
after at least two lines of systemic therapy.

LuciPirto

including a BTK inhi bitor.

Dosage anu Ooc.

The racommer
The recommended dosage of LuciPirto is
300 ma orallu
200 mg orally once daily; swallow whole
with water, with or without food. Do not cut

Pirtobrutinib Tablets

FDA批准

crush, or chew tablets.
Storage: in a dry place and store at 20C to
25C

Wornings

50mg

Warning:
Keep medicine out of reach of Children. Do
not administer LuciPirto during Pregnancy
PLEASE SEE PACKAGE INSERT

Rx only

Manufactured and Marketed by
LUCIUS

权威认证

PHARMACEUTICALS
Thonen
Thongmang village, Xaythany district,
Vientiane Capital, Laos
www.lucius.la
Warning : To be sold by retail on prescription
of registered physicians only, and as directe
hs piysician.

30 Tablets

口碑质量

适应症:
适用于治疗经过至少两种系统治疗(包括BTK抑制剂)
后复发或难治性套细胞淋巴瘤(MCL)的成年患者。
推荐剂量:
每日口服一次,每次200mg,随餐或不随餐均可。